Taro Vit Industries
Is correct name of multi-national pharmaceutical firm. Company's 1988 sales rose 5.2% to U.S. $9.3 mil. and net income was U.S. $119,000 compared to $11,000 in 1987. Fourth quarter sales declined 22% to U.S. $2.2 mil. due to a sudden devaluation of the Israeli shekel on Dec. 31, firm said. Taro Vit's name and sales and earnings numbers were incorrect in the April 17 edition.
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”